This page contains brief information about ibrutinib and a collection of links to more information about the use of this drug, research results, and ongoing clinical trials.
|US Brand Name(s):||Imbruvica|
Ibrutinib is approved to treat:
- Chronic lymphocytic leukemia in patients who have already received other treatment.
- Mantle cell lymphoma in patients who have already received other treatment.
Ibrutinib is also being studied in the treatment of other types of cancer.More About Ibrutinib
Definition from the NCI Drug Dictionary - Detailed scientific definition and other names for this drug.Research Results
Investigational Targeted Drug Induces Responses in Aggressive Lymphomas - Information from the NCI Press Office about this drug.
Targeted Drug Shows Promise in Common Form of Lymphoma - Information about the use of this drug to treat cancer.Clinical Trials Accepting Patients
Find Clinical Trials for Ibrutinib - Check for trials from NCI's list of cancer clinical trials now accepting patients.
Important: The drug information on this page is meant to be educational. It is not a substitute for medical advice. The information may not cover all possible uses, actions, interactions, or side effects of this drug, or precautions to be taken while using it. Please see your health care professional for more information about your specific medical condition and the use of this drug.